CA2873112A1 - Site-specific labeling and targeted delivery of proteins for the treatment of cancer - Google Patents

Site-specific labeling and targeted delivery of proteins for the treatment of cancer Download PDF

Info

Publication number
CA2873112A1
CA2873112A1 CA2873112A CA2873112A CA2873112A1 CA 2873112 A1 CA2873112 A1 CA 2873112A1 CA 2873112 A CA2873112 A CA 2873112A CA 2873112 A CA2873112 A CA 2873112A CA 2873112 A1 CA2873112 A1 CA 2873112A1
Authority
CA
Canada
Prior art keywords
protein
annexin
formula
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873112A
Other languages
English (en)
French (fr)
Inventor
Alexander Krantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Proteome Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2873112A1 publication Critical patent/CA2873112A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2873112A 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer Abandoned CA2873112A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261688308P 2012-05-11 2012-05-11
US61/688,308 2012-05-11
US201261741984P 2012-08-01 2012-08-01
US61/741,984 2012-08-01
US201361848601P 2013-01-07 2013-01-07
US61/848,601 2013-01-07
US201361849034P 2013-01-17 2013-01-17
US61/849,034 2013-01-17
PCT/US2013/040823 WO2013170272A2 (en) 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2873112A1 true CA2873112A1 (en) 2013-11-14

Family

ID=49551481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873112A Abandoned CA2873112A1 (en) 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer

Country Status (5)

Country Link
US (1) US9545449B2 (enExample)
EP (1) EP2850201A4 (enExample)
JP (1) JP6290187B2 (enExample)
CA (1) CA2873112A1 (enExample)
WO (1) WO2013170272A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5149620B2 (ja) 2004-07-23 2013-02-20 エンドサイト，インコーポレイテッド ２価リンカーおよびその結合体
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
ES2759503T3 (es) 2013-05-02 2020-05-11 Glykos Finland Oy Conjugados de una glicoproteína o un glicano con una carga útil tóxica
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
EA201692530A1 (ru) 2014-06-13 2017-07-31 Новартис Аг Цитотоксические пептиды и их конъюгаты
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
MX381031B (es) * 2015-08-11 2025-03-12 Coherent Biopharma | Ltd Conjugados fármaco-multiligando y usos de los mismos.
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2018136455A1 (en) * 2017-01-17 2018-07-26 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
WO2020247151A1 (en) * 2019-06-05 2020-12-10 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
EP4366780A1 (en) * 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Synthetic il-7 and il-7 immunocytokines
WO2023281482A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Cd20-targeted il-2 and its uses
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066490A (en) 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
EP1001968B1 (en) 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
WO2002042427A2 (en) 2000-10-25 2002-05-30 Surromed, Inc. Mass tags for quantitative analysis
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030215877A1 (en) 2002-04-04 2003-11-20 California Institute Of Technology Directed protein docking algorithm
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070123465A1 (en) 2004-06-18 2007-05-31 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of hiv infections
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
WO2009158668A1 (en) * 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2350112A4 (en) * 2008-10-03 2013-01-16 Advanced Proteome Therapeutics Inc Site specific N-termin protein modifications and conjugate formation
CA2764029C (en) 2009-06-03 2019-10-29 Mosamedix B.V. Method for enhancing phagocytosis of phosphatidylserine-exposing cells
WO2011103409A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
WO2011140392A1 (en) * 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
WO2011153250A2 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives

Also Published As

Publication number Publication date
WO2013170272A2 (en) 2013-11-14
JP6290187B2 (ja) 2018-03-07
EP2850201A2 (en) 2015-03-25
US20150202314A1 (en) 2015-07-23
US9545449B2 (en) 2017-01-17
WO2013170272A3 (en) 2014-02-27
EP2850201A4 (en) 2016-08-31
JP2015519339A (ja) 2015-07-09

Similar Documents

Publication Publication Date Title
US9545449B2 (en) Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
JP7564143B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
US20260001916A1 (en) Cyclic cell-penetrating peptide compounds
US20170333563A1 (en) Drug delivery vehicle
ES2349743T3 (es) Derivados de la il-21.
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
US20240368224A1 (en) Bicyclic peptidyl pan-ras inhibitors
WO2010028389A1 (en) Image-guided energy deposition for targeted drug delivery
WO2018160759A1 (en) Zwitterionic dendritic amphiphiles, zwitterionic dendrimers, zwitterionic telodendrimers, nanocarriers comprising same, and methods of making and using same
WO2023077126A1 (en) Trans-cyclooctene conjugates
WO2023077129A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
PL238187B1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
US10556928B2 (en) Stabilized peptoid-peptide hybrids and uses thereof
US20220257805A1 (en) Pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to cd206
CN118369123A (zh) 用于有效载荷的体内靶向递送的四嗪缀合物
CN121419788A (zh) 用于体内递送有效载荷的基于四嗪的靶向剂
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
WO2025059685A1 (en) Methods for in vivo targeted delivery of a payload
HK40108922A (zh) 用於有效载荷的体内靶向递送的四嗪缀合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180511

FZDE Discontinued

Effective date: 20240112